Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
5 search results for:

Selpercatinib 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 15-05-2020 | FDA | News | Article
    approvalsWatch

    Selpercatinib receives FDA nod

    medwireNews : The US FDA has approved selpercatinib  for the treatment of advanced lung and thyroid cancers with RET alterations.

    Author:
    Shreeya Nanda
  2. 12-09-2019 | Non-small-cell lung cancer | News | Article

    LIBRETTO-001: Selpercatinib achieves high ORRs in RET fusion-positive NSCLC

    Selpercatinib elicits deep antitumor responses and is well tolerated by patients with advanced non-small-cell lung cancer harboring RET fusions, show updated trial data presented at the IASLC World Conference on Lung Cancer 2019.

    Published in:
    IASLC World Conference on Lung Cancer 2019; Barcelona, Spain: 7–10 September
  3. 24-12-2020 | EMA | News | Article
    approvalsWatch

    EMA adopts positive opinions for breast, lung, GU cancer indications

    Selpercatinib may be given to NSCLC patients who require system treatment after receiving immunotherapy and/or platinum-based chemotherapy.

    Author:
    Lynda Williams
  4. play
    08-06-2020 | ASCO 2020 | Conference coverage | Video

    Expert highlights: Targeted therapy for ALK-, RET- and MET-driven NSCLC

    Tejas Patil rounds up findings from the ALEX, ALTA-1L, ARROW, LIBRETTO-001, GEOMETEY mono-1 and VISION studies of non-small-cell lung cancer patients with ALK, RET, or MET alterations (9:56).

  5. LIBRETTO-001 trial

    Updated data presented at the World Conference on Lung Cancer 2019 demonstrated that selpercatinib elicits deep antitumor responses and is well tolerated by patients with advanced NSCLC harboring RET fusions .

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.